$3.06
▲ +$0.05
(+1.66%)
Vol 106K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$137.8M
ROE
-138.2%
Margin
-29.9%
D/E
144.54
Beta
1.90
52W
$3–$12
Wall Street Consensus
11 analysts · Apr 20263
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
GANX
Gain Therapeutics Inc
$123.8M
INO
Inovio Pharmaceuticals Inc
$119.5M
SERA
Sera Prognostics Inc
$113.9M
COEP
Coeptis Therapeutics Holdings Inc
$76.1M
EXOZ
eXoZymes Inc
$91.4M
PMVP
PMV Pharmaceuticals Inc
$66.5M
BYSI
Beyondspring Inc
$67.0M
MNOV
MediciNova Inc
$64.4M
DWTX
Dogwood Therapeutics Inc
$123.7M
XBIT
XBiotech Inc
$72.9M
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.19 | $-0.20 | $-0.01 |
| Sep 2025 | $-0.16 | $-0.31 | $-0.15 |
| Jun 2025 | $-0.14 | $-0.18 | $-0.04 |
| Mar 2025 | $-0.20 | $-0.20 | +$0.00 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -136.3% | -136.3% | -136.3% | -136.3% | -138.2% | -138.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -25.8% | -28.9% | -28.9% | -28.9% | -29.9% | -29.9% |
| Gross Margin | 60.4% | 59.4% | 59.4% | 59.4% | 59.9% | 59.9% |
| D/E Ratio | 109.24 | 109.24 | 109.24 | 109.24 | 144.54 | 144.54 |
| Current Ratio | 4.95 | 4.95 | 4.95 | 4.95 | 4.08 | 4.08 |
Key Ratios
ROA (TTM)
-36.9%
P/S (TTM)
2.17
P/B
7.6
EPS (TTM)
$-0.93
CF/Share
$-1.45
Rev Growth 3Y
+4.8%
52W High
$12.23
52W Low
$2.67
$2.67
52-Week Range
$12.23
How does XGN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
XGN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2.2
▼
83%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
7.6
▲
208%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
XGN profitability vs Biotechnology peers
ROE
-138.2%
▼
105%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-29.9%
▲
90%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
59.9%
▼
24%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-36.9%
▲
21%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
XGN financial health vs Biotechnology peers
D/E ratio
144.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.1
▼
8%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.9
▲
96%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
XGN fundamentals radar
XGN
Peer median
Industry
XGN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
XGN vs peers: key metrics
Latest News
No related news yet